Evidence map›Paper›PMID 38260414›Full record

ArticlebioRxiv : the preprint server for biology2024

Genomic dissection and mutation-specific target discovery for breast cancer

Adam X Miranda, Justin Kemp, Brad Davidson, Sara Erika Bellomo, Verda Agan, Alexandra Manoni, Caterina Marchiò, Sarah Croessmann, Ben H Park, Emily Hodges

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Adam X MirandaDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-3140-1953
Justin KempDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Brad DavidsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-5850-117X
Sara Erika BellomoCandiolo Cancer Institute, FPO-IRCCS, Candiolo, TO, Italy.
Verda AganDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA.
Alexandra ManoniDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Caterina MarchiòCandiolo Cancer Institute, FPO-IRCCS, Candiolo, TO, Italy.ORCID 0000-0003-2024-6131
Sarah CroessmannDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-7366-0400
Ben H ParkDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Emily HodgesDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID 0000-0001-6513-610X
Vanderbilt University Medical Center · USCandiolo Cancer Institute · ITVanderbilt University · USBreast Cancer Research Foundation · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7M
Circulating plasma tumor DNA as a biomarker for early stage breast cancerR01CA194024 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO · 2016 to 2020
$1.9M
Decoding genome function with DNA methylation and human phenome dataR01GM147078 · NIGMS · VANDERBILT UNIVERSITY · PI Emily Hodges · 2022 to 2026
$1.9M
Molecular complete response in blood as a predictor for pathologic complete response after neoadjuvant therapy for breast cancerR01CA214494 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO · 2018 to 2023
$1.1M
NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA098131NCI NIH HHS R01 CA194024NCI NIH HHS R01 CA214494NIGMS NIH HHS R01 GM147078
6 · The paper itself

Abstract

Background: Recent advancements in high-throughput genomics and targeted therapies have provided tremendous potential to identify and therapeutically target distinct mutations associated with cancers. However, to date the majority of targeted therapies are used to treat all functional mutations within the same gene, regardless of affected codon or phenotype. Results: In this study, we developed a functional genomic analysis workflow with a unique isogenic cell line panel bearing two distinct hotspot Conclusions: Using our multi-modal genomics framework, we discover distinct differences in genomic regulation between

Indexed as

breast cancerchromatin accessibilityepigenomicsgene expressionIntegrative analysisisogenic cell linesPIK3CA

Identifiers

PMID38260414
PMCPMC10802285
OpenAlexW4390649755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.